Preliminary effectiveness and safety in the first 88 patients with newly diagnosed locally advanced basal cell carcinoma treated with vismodegib in the RegiSONIC Disease Registry study - 21/04/16
Mario E. Lacouture, MD, Memorial Sloan-Kettering Cancer Center, New York, NY, United States; Jean Y. Tang, MD, PhD, Stanford University School of Medicine, Redwood City, CA, United States; Gary Rogers, MD, Tufts University School of Medicine, Beverly, MA, United States; Thomas Olencki, DO, Ohio State University Medical Center, Columbus, OH, United States; Ragini R. Kudchadkar, MD, Emory University, Atlanta, GA, United States; Simon Yoo, MD, Northwestern University, Chicago, IL, United States; Julie Guillen, RN, MSN, University of California, San Francisco, San Francisco, CA, United States; Yong Mun, PhD, Genentech, Inc, South San Francisco, CA, United States; Keith Dawson, MS, Genentech, Inc, South San Francisco, CA, United States; Aleksandar Sekulic, MD, PhD, Mayo Clinic Scottsdale, Scottsdale, AZ, United States
Le texte complet de cet article est disponible en PDF.| Supported by F. Hoffmann-LaRoche. |
Vol 74 - N° 5S1
P. AB202 - mai 2016 Retour au numéro
Article précédent
- Penile squamous cell carcinoma in two patients treated with mycophenolate mofetil in a dermatologic setting
- Prevalence of actinic keratosis in general practice in Switzerland
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?